Remedy Robotics has raised $62 million in Series B funding to move its AI-enabled surgical robot toward clinical trials and potential FDA approval, targeting a major gap in stroke care: most hospitals cannot offer urgent specialist procedures.
The San Francisco company is developing N1, a robotic platform designed to perform catheter-based interventions inside blood vessels. DCVC led the round, joined by new investors UC Investments, Skip Capital and Hostplus. Returning backers include Tony Fadell’s Build Collective, Blackbird, Divergent Capital and KdT Ventures.
Remedy will use the funding for a planned pivotal trial with the University of California, prototype deployments with clinical partners, and continued work on remote operation and autonomous capabilities. Partners include SVIN Mission Thrombectomy and the Australian Stroke Alliance.
N1 uses machine learning to study scans before surgery, simulate a procedure and align three-dimensional anatomy with live two-dimensional imaging. It is being designed to let specialists control the robot on-site or remotely, rather than requiring the physician to be physically beside the patient.
The company says it works with more than 100 hospitals worldwide. In October 2025, Remedy reported completing fully remote neurointerventional procedures in Toronto: clinicians operated from one hospital while patients were at another, without a specialist performing the intervention at the bedside.
That milestone is promising, but it is not regulatory clearance. N1 remains investigational and is not available for sale or clinical use. The next question is whether larger trials can demonstrate the safety, effectiveness and consistency needed to turn remote robotic procedures into everyday hospital care.
Get stories like this in your inbox every week. Subscribe to The Week in Perspective.
Sources: Remedy Robotics announcement; Remedy N1 technology.

